ClinicalTrials.gg
RecruitingNCT05503966DEPTREATUpdated Mar 28, 2025

Combining Antidepressants and Attention Bias Modification in Depression

An interventional study of Attentional Bias Modification in Depressive Disorder, sponsored by University of Oslo. Recruiting at 1 site in Norway. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-03-28.

Sponsored by University of Oslo · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Mar 2025, 1 year 7 months ago, but the record still lists the study as recruiting.
  • Started Sep 2022; still recruiting 4 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
246
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Depressive Disorder with a site in Norway — 4 open to participants now, 5 under way, none of them phase 3. Depressive Disorder · Norway.

Planned enrollment
2nd of 10
246 · median 52
Started
2022
the only one that year
No phase
7 of 15
3 open now
Registered
13th of 15
by date

Among the 15 studies in Depressive Disorder with a site in Norway, this one is the 2nd largest by planned enrollment of the 10 interventional ones that give a count, is the only one that started in 2022, is one of 7 with no phase, and was the 13th registered.

Depressive Disorder

857 studies on the registry are indexed under Depressive Disorder; 160 are open to participants now.

Browse Depressive Disorder studies →

Open to participants now

4 of the 15 studies in Depressive Disorder with a site in Norway are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Norway have not opened yet or have stopped. Only those recruiting at a site in Norway →

Who these studies take

Of the 116 Depressive Disorder studies recruiting now, 44 (38%) set no upper age limit and 66 (57%) stop at 75 or younger; 24 take children under 18; 25 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Depressive Disorder with a site in Norway, or all of them as a file.
02

Study summary

Background: Major depressive disorder (MDD) is a highly prevalent psychiatric condition associated with significant disability, mortality and economic burden. A large proportion of MDD patients are treated in primary health care (PHC) in the municipalities and represent a challenging group. Attentional Bias Modification (ABM) training in combination with antidepressants (SSRIs) could be an effective treatment. The overall aim of this study is to test the hypothesis that adding an ABM procedure to regular treatment with antidepressants in PHC will result in further improvement of symptoms compared to treatment with antidepressants alone (treatment as usual, TAU) and as compared to an active comparison condition.

Methods: A total of 246 patients with a diagnosis of MDD will be included in this study. The study is a three-armed pragmatic randomized controlled trial comparing the efficacy of ABM as add-on to treatment with antidepressants in primary care (ABM condition) compared to standard antidepressant treatment (TAU condition). In a third group participants will complete the same schedule of intermediate assessments as the ABM condition in addition to TAU , but no ABM, thus controlling for the non-training-specific aspects of the ABM condition (SSRI Active comparison group).

Discussion:

The clinical outcome of this study may help develop easy accessible, low cost treatment of depression in PHC. Moreover, the study aims to broaden our knowledge of optimal treatment for patients with a MDD by providing adjunct treatment to facilitate recovery and long term gain

Read the detailed description

Major Depressive Disorder (MDD) is a debilitating disorder that affects 15% of the population and is a leading cause of disability worldwide. The economic burden of MDD is enormous, with estimates of direct/indirect costs of $210.2 billion/year in the US alone.

Although both psychotherapy and antidepressant medications are effective, it is not uncommon for a patient with MDD to have temporary symptom reduction after treatment but require an extended amount of time for full restoration of function. A large proportion of MDD patients are treated in PHC in the municipalities and represent a challenging group to treat effectively. At the same time, it is known that early treatment and coordinated follow-up can be efficient even without costly specialist interventions or hospital treatment. Thus, improved treatment of MDD in municipalities represents a tremendous opportunity for improvement of public health and well being in the general population.

Considerable progress has been made in characterizing mechanisms underlying depression vulnerability and this may be harnessed to improve future treatment strategies. The ability to deal effectively with stress and life events is influenced by the ability of the brain to rapidly adapt, which in turn is a function of synaptic plasticity. Further, it has been hypothesized that the capacity of synapses for functional and structural change plays an important role in the pathophysiology and treatment of mood disorders. These dysfunctional neural mechanisms are affected by antidepressants and increased synaptic plasticity may be one of the therapeutic mechanisms. However, enhancing plasticity alone may not lead to a sufficient treatment response in all individuals affected by depression. Indeed, the entrenched attentional biases seen in depression, such as the tendency to focus on and recall negative information, may persist and be further entrenched by changes in the neural underpinnings of learning and memory. Furthermore, negative attention biases are associated with persistence of sad mood in major depressive disorder. However, selective biases in attention can potentially be modified by a simple computerized technique: The Attention Bias Modification Task (ABM).

While some studies have reported an effect of ABM in depression, definitive conclusions have been limited by small samples and poor trial methodology in many studies. However, recently a large RCT study showed that ABM training led to significantly greater decrease in clinician-rated symptoms of depression as compared to the control condition. ABM induced a change in AB towards relatively more positive stimuli for participants that also showed greater symptom reduction. A secondary network analysis indicated that ABM primarily influenced the symptom "interest" which could mediate both symptoms, social support, functioning and quality of life. Furthermore, a sub-sample was included in a brain imaging study revealing that the ABM active group showed reduced activation in the amygdala and the anterior cingulate cortex when passively viewing negative images compared to the sham group. Other studies have also found that experimentally modifying negatively biased attention reduces depressive symptoms. However, some studies have showed that ABM is not significantly better in improving depressive symptoms as compared to sham.

In addition to explore mechanisms of neuroplasticity, in parallel research there has also been interest in understanding the effects of antidepressant drugs on psychological processes involved in depression. Thus, a number of studies for more than a decade have documented that SSRIs modify biases in emotional processing, thus they work by modifying the same underlying basic mechanism that are the focus when applying ABM procedures. Emotional processing is influenced early in the treatment and independently of change in subjective mood, and these effects have been shown in depressed subjects as well as in healthy volunteers. Most of these studies investigated the effects of a single dose of an SSRI compared with placebo. However, it has been showed that antidepressants as prescribed in the community also increases processing for positive information.

A logical next step is to combine SSRIs as prescribed in primary health with an ABM procedure. Combining pharmacological and psychological regimes are gold standard treatment options in both depression and anxiety and is not associated with baseline severity.Treatments, such as cognitive behavioral therapy (CBT) might also change attentional biases, but by implementing an ABM procedure we will more readily target these biases directly. By combining ABM with today's treatment options, we could potentially increase treatment efficacy and shorten treatment duration. Furthermore, ABM has the advantage of being entirely deliverable on a digital platform without the need for therapist interaction.

The main aim of this study is to test the hypothesis that adding an ABM procedure to regular treatment with antidepressants in PHC will result in a clinically important improvement of symptoms compared to treatment with antidepressants alone (TAU), and as compared to an active comparison condition. Secondary aims are to investigate possible effects of the combined treatment on anxiety symptoms, emotional blunting, rumination, perceived stress, psychosocial functioning/work and suicidal risk. Thirdly, a number of potential moderators will also be investigated.

03

Conditions studied

  • Depressive Disorder

Keywords

  • Major Depressive Disorder
  • Attentional Bias Modification
  • Primary Health Care
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Major Depressive Disorder
  • BDI II > 14
  • Age 18 - 65 years
  • Ability to understand and speak a Scandinavian language
  • Willingness and ability to give

Exclusion criteria

Exclusion Criteria:

  • Current or past neurological illness
  • Traumatic brain injury
  • Current alcohol and/or substance dependency disorders
  • Psychotic disorders
  • Bipolar disorder type 1,
  • Developmental disorders and mental retardation.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
246 participants (estimated)

Study arms

  • Experimental
    Positive ABM

    The ABM intervention will be initiated two weeks after antidepressant treatment started (baseline) and continues with two daily sessions for two weeks.

    Behavioral: Attentional Bias Modification

  • Active comparator
    No ABM

    This group will in addition to TAU complete the schedule of intermediate assessments as in the ABM group, but no ABM , thus controlling for the aspects of the ABM group that are additional to TAU (increased engagement in cognitive activity and repeated assessment over time), but not including the training component itself (SSRI Active comparison group).

    Behavioral: Attentional Bias Modification

  • No intervention
    TAU

    Patients allocated to this group will be assessed at baseline and at the primary end-point as well after 12 weeks and 6 months follow-up. They will not complete any instruments during the intervention period to prevent the effect of some cognitive activity and provide a more ecologically valid version of TAU as it happens in primary care.

Interventions

  • BehavioralAttentional Bias Modification

    The ABM task is based on a computerized visual Dot-probe task. In the dot-probe task paired stimuli of negative (angry and fearful), positive (happy) or neutral faces are presented, followed by one or two probes (dots) appearing in the spatial location of one of the stimuli. Participants are then required to press one of two buttons as quickly as possible to indicate the number of dots in the probe. In the ABM condition, probes are in the same locus as the more positive/less negative stimuli in 87% of the trials, as opposed to 13% with probes in the same locus as more negative/less positive stimuli. Thus, when completing the ABM, participants should learn to deploy their attention toward the relatively more positive stimuli, and in this way develop a more positive AB.

    Also known as: ABM

06

What researchers measure

Primary outcomes

  1. Hamilton Depression Rating Scale

    Clinician rated depressive symptoms. Range (0-50). Higher score indicate more depressive symptoms

    Time frame: 8 weeks after baseline.

  2. Beck Depression Inventory II

    Self rated depressive symptoms. Range (0-63). Higher score indicate more depressive symptoms

    Time frame: 8 weeks after baseline.

Secondary outcomes

  1. Beck Depression Inventory II

    Self rated depressive symptoms, Range (0-63). Higher score indicate more depressive symptoms

    Time frame: Follow-up 12 weeks after baseline.

  2. Beck Depression Inventory II

    Self rated depressive symptoms, Range (0-63). Higher score indicate more depressive symptoms

    Time frame: Follow-up 6 months after baseline

  3. Generalized Anxiety Disorder-7

    Self rated anxiety symptoms. Range (0-21). Higher score indicate more anxiety symptoms

    Time frame: 8 weeks after baseline.

  4. Generalized Anxiety Disorder-7

    Self rated anxiety symptoms. Range (0-21). Higher score indicate more anxiety symptoms

    Time frame: 12 weeks after baseline.

  5. Generalized Anxiety Disorder-7

    Self rated anxiety symptoms. Range (0-21). Higher score indicate more anxiety symptoms

    Time frame: 6 months after baseline

  6. Oxford Depression Questionnaire

    Self rated emotional blunting symptoms. Range (0-80). Higher score indicate more symptoms.

    Time frame: 8 weeks after baseline

  7. Oxford Depression Questionnaire

    Self rated emotional blunting symptoms. Range (0-80). Higher score indicate more symptoms.

    Time frame: 12 weeks after baseline.

  8. Oxford Depression Questionnaire

    Self rated emotional blunting symptoms. Range (0-80). Higher score indicate more symptoms.

    Time frame: 6 months after baseline

  9. Rumination Response Scale

    Self rated level of rumination. Range (22-88). Higher score indicate more rumination.

    Time frame: 8 weeks after baseline.

  10. Rumination Response Scale

    Self rated level of rumination. Range (22-88). Higher score indicate more rumination.

    Time frame: 12 weeks after baseline

  11. Rumination Response Scale

    Self rated level of rumination. Range (22-88). Higher score indicate more rumination.

    Time frame: 6 months after baseline

  12. The Perceived Stress Scale

    Self rated subjective level of stress. Range (0-40). Higher score indicate more perceived stress.

    Time frame: 8 after baseline

  13. The Perceived Stress Scale

    Self rated subjective level of stress. Range (0-40). Higher score indicate more perceived stress.

    Time frame: 12 weeks after baseline

  14. The Perceived Stress Scale

    Self rated subjective level of stress. Range (0-40). Higher score indicate more perceived stress.

    Time frame: 6 months after baseline

  15. The Work and Social Adjustment Scale

    Self rated level of social functioning. Range (0-40). Higher score indicate poorer functioning

    Time frame: 8 weeks after baseline.

  16. The Work and Social Adjustment Scale

    Self rated level of social functioning. Range (0-40). Higher score indicate poorer functioning

    Time frame: 12 weeks after baseline.

  17. The Work and Social Adjustment Scale

    Self rated level of social functioning. Range (0-40). Higher score indicate poorer functioning

    Time frame: 6 months after baseline.

  18. Bergen Insomnia Scale

    Self rated level of sleep problems. Range (0-42). Higher score indicate more insomnia

    Time frame: 8 weeks after baseline.

  19. Bergen Insomnia Scale

    Self rated level of sleep problems. Range (0-42). Higher score indicate more insomnia

    Time frame: 12 weeks after baseline.

  20. Bergen Insomnia Scale

    Self rated level of sleep problems. Range (0-42). Higher score indicate more insomnia

    Time frame: 6 months after baseline.

  21. Beck depression Inventory II (Suicid item)

    Self reported level of suicidality. Range (0-3). Higher score indicate more suicidality.

    Time frame: 8 weeks after baseline.

  22. Beck depression Inventory II (Suicid item)

    Self reported level of suicidality. Range (0-3). Higher score indicate more suicidality.

    Time frame: 12 weeks after baseline.

  23. Beck depression Inventory II (Suicid item)

    Self reported level of suicidality. Range (0-3). Higher score indicate more suicidality.

    Time frame: 6 months after baseline.

  24. Dot probe

    Degree of attentional bias- Measure mean reaction time.

    Time frame: 8 weeks after baseline.

  25. Dot probe

    Degree of attentional bias- Measure mean reaction time.

    Time frame: 12 weeks after baseline

  26. Dot probe

    Degree of attentional bias- Measure mean reaction time.

    Time frame: 6 months after baseline.

  27. Facial Expression Rating Task

    Measure of detection threshold for correctly identifying the emotional facial expression. Measures of number of correct answer (Range 0-100%)

    Time frame: 8 weeks after baseline

  28. Facial Expression Rating Task

    Measure of detection threshold for correctly identifying the emotional facial expression. Measures of number of correct answer (Range 0-100%)

    Time frame: 12 weeks after baseline

  29. Facial Expression Rating Task

    Measure of detection threshold for correctly identifying the emotional facial expression. Measures of number of correct answer (Range 0-100%)

    Time frame: 6 months after baseline

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided — Anonymized data may be shared on request

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2022 (actual). Primary completion is estimated for Mar 2025, 30 months after the start.

Of 261 non-industry interventional studies with no phase under Depressive Disorder, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 45. This study's planned 30 months is close to that.

Counting every sponsor, half of 276 studies reached it within 29 months; a quarter within 15 and three quarters within 45.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 9, 2022
First posted
Aug 17, 2022
StartActual
Sep 22, 2022
Primary completionEst.
Mar 30, 2025
CompletionEst.
Dec 30, 2025
Last update
Mar 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05503966
Lead sponsor
University of Oslo
Responsible party
Jan Ivar Rossberg (Professor, University of Oslo) — Principal investigator
First posted
Aug 17, 2022
Start date
Sep 22, 2022
Primary completion
Mar 30, 2025 (estimated)
Completion
Dec 30, 2025 (estimated)
Last update
Mar 28, 2025

Study contacts

Jan I Røssberg, PhD
Contact
j.i.rossberg@medisin.uio.no
+47 47876866
Nils I Landrø, PhD
Contact
n.i.landro@psykologi.uio.no
+47 95038479
Jan I Røssberg, PhD
principal investigator · Universitetet i Oslo/Oslo universitetssykehus

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion